Literature DB >> 10397601

Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect.

N M Concessio1, M M VanOort, M R Knowles, A J Hickey.   

Abstract

PURPOSE: Efficient dispersion of bulk solids is critical for dry powder aerosol production which can be viewed as a sequence of events from stationary through dilated, flowing and finally dispersed particulates. The purpose of this study was to test the hypothesis that numerical descriptors of powder flow properties predict aerosol dispersion and pharmacodynamic effect.
METHODS: Drug and excipient particles were prepared in size ranges suitable for inhalation drug delivery, and their physico-chemical properties were evaluated. Novel techniques (chaos analysis of dynamic angle of repose and impact force separation) were developed and utilized to measure and characterize powder flow and particle detachment from solid surfaces, respectively. Dry powder aerosol dispersion was evaluated using inertial impaction. Pharmacodynamic evaluations of bronchodilation were performed in guinea pigs, for selected formulations.
RESULTS: We observed a direct correlation of powder flow with ease of particle separation (r2=0.9912) and aerosol dispersion (r2= 0.9741). In vivo evaluations indicated that formulations exhibiting a higher in vitro dose delivery resulted in a greater reduction in pulmonary inflation pressure.
CONCLUSIONS: These results integrate powder behavior at various levels and indicate that numerical descriptors of powder flow accurately predict dry powder aerosol dispersion. A proportionality between aerosol dispersion and pharmacodynamic effect was observed in preliminary in vivo evaluations, which demonstrates the potential of these techniques for correlation studies between in vitro powder properties and in vivo effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397601     DOI: 10.1023/a:1018865717374

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  11 in total

1.  Descriptors of irregular particle morphology and powder properties.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-06-09       Impact factor: 15.470

2.  An investigation into the deposition of inhalation aerosol particles as a function of air flow rate in a modified 'Kirk Lung'.

Authors:  P J Davies; G W Hanlon; A J Molyneux
Journal:  J Pharm Pharmacol       Date:  1976-12       Impact factor: 3.765

3.  Induction by aerosol allergen of sustained and nonspecific IgE-mediated airway hyperreactivity in the guinea pig.

Authors:  D A Handley; J J DeLeo; A M Havill
Journal:  Agents Actions       Date:  1992-11

4.  Deposition and dispersion of aerosols in the airways of the human respiratory tract: the effect of particle size.

Authors:  G Scheuch; W Stahlhofen
Journal:  Exp Lung Res       Date:  1992 May-Jun       Impact factor: 2.459

5.  Measurements of the adhesive force between particles of powdered organic substances and a glass substrate by means of the impact separation method. II. Effect of addition of light anhydrous silicic acid on the adhesive force of potato starch.

Authors:  A Otsuka; K Iida; K Danjo; H Sunada
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-09       Impact factor: 1.645

Review 6.  Therapeutic aerosols 1--physical and practical considerations.

Authors:  S P Newman; S W Clarke
Journal:  Thorax       Date:  1983-12       Impact factor: 9.139

7.  Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler.

Authors:  R M Auty; K Brown; M G Neale; P D Snashall
Journal:  Br J Dis Chest       Date:  1987-10

8.  Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF.

Authors:  J S Franzone; R Cirillo; P Biffignandi
Journal:  Eur J Pharmacol       Date:  1989-06-20       Impact factor: 4.432

9.  Severe acute asthma: a comparison of three methods of inhaling salbutamol.

Authors:  B A Webber; J V Collins; M A Branthwaite
Journal:  Br J Dis Chest       Date:  1982-01

10.  The booster injection of antigen during active sensitization of guinea-pig modifies the anti-anaphylactic activity of the PAF antagonist WEB 2086.

Authors:  S Desquand; J Lefort; C Dumarey; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

View more
  7 in total

1.  Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.

Authors:  Vasu V Sethuraman; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

Review 2.  Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

3.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

Review 4.  Particle transport and deposition: basic physics of particle kinetics.

Authors:  Akira Tsuda; Frank S Henry; James P Butler
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

5.  Trimellitic anhydride (TMA) dust induces airway obstruction and eosinophilia in non-sensitized guinea pigs.

Authors:  Christen P Larsen; Jean F Regal
Journal:  Toxicology       Date:  2002-09-02       Impact factor: 4.221

6.  Evaluation of granulated lactose as a carrier for DPI formulations 1: effect of granule size.

Authors:  Ping Du; Ju Du; Hugh D C Smyth
Journal:  AAPS PharmSciTech       Date:  2014-06-25       Impact factor: 3.246

7.  Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder inhaler formulations.

Authors:  Rinku A Tuli; Graeme A George; Tim R Dargaville; Nazrul Islam
Journal:  Pharm Res       Date:  2012-05-15       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.